Daily close, T-120 (10/21/25) through T+5. Run-up high $2.47 on 12/23/25, low $0.198 on 3/25/26 (T-120 to T-1). FDA decision 4/7/26. Historical price action, not a forecast.
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Questions
Was LYTENAVA (bevacizumab-vikg) approved by the FDA?
Not in this review cycle. A Complete Response Letter, declining to approve the application for LYTENAVA (bevacizumab-vikg) in its current form, was announced on April 7, 2026. A CRL is not final; the primary source is linked on this page.
Which company is behind LYTENAVA (bevacizumab-vikg)?
LYTENAVA (bevacizumab-vikg) is an Outlook Therapeutics Inc. (OTLK) program. The company announced the FDA decision on April 7, 2026; the primary source is linked on this page.
How did OTLK stock trade into the FDA decision?
Measured over the 120 trading days before the decision (T-120 to T-1), OTLK moved -84.7%. That is the recorded price path into this specific event. Historical measurement, not a prediction, and not investment advice.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.